{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:43:26Z","timestamp":1791290606707,"version":"4.3.0"},"reference-count":128,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi Pasteur SA, Lyon, France"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/14760584.2021.1964962","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T07:15:00Z","timestamp":1628493300000},"page":"1123-1146","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[{"name":"Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Cl\u00ednico Universitario and Universidad De Santiago De Compostela (USC), Galicia, Spain"},{"name":"Genetics, Vaccines, and Pediatric Infectious Diseases Research Group (GENVIP), Instituto De Investigaci\u00f3n Sanitaria De Santiago and Universidad De Santiago De Compostela (USC), Galicia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bertrand-Gerentes","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi Pasteur, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi Pasteur, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-346-2_1"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.062"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix993"},{"key":"cit0004","unstructured":"World Health Organization (WHO). Meningococcal meningitis - Fact sheet Geneva, Switzerland: World Health Organization (WHO); 2018 [updated Jan 2018; cited 2021 Feb 23]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs141\/en\/"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.03.041"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010409"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.04.012"},{"key":"cit0009","unstructured":"United States Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018 Atlanta, Georgia: Centers for Disease Control and Prevention; 2018 [2021 Jan 8]. Available from: https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2018.pdf"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/BF02918259"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.4161\/viru.26515"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13760"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4146-5"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00048-09"},{"key":"cit0015","first-page":"1","volume":"15","author":"Taha MK","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.058"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.036"},{"key":"cit0018","unstructured":"European Center for Disease Prevention and Control. Surveillance Atlas of infectious diseases - invasive meningococcal disease. Solna, Sweden: European Center for Disease Prevention and Control; 2017 [updated 2017;2021 Jan 8]. Available from: https:\/\/atlas.ecdc.europa.eu\/public\/index.aspx?Dataset=27&HealthTopic=36"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22302"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1258308"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2018.05.003"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03502-9"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz578"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu881"},{"key":"cit0025","unstructured":"Public Health England. Meningococcal group W (MenW) immunisation advised for 14 to 18 year-olds. London, UK: Public Health England; 2015 [updated 2015 Mar 13;2021 Jan 9]. Available from: https:\/\/www.gov.uk\/government\/news\/meningococcal-group-w-menw-immunisation-advised-for-14-to-18-year-olds"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30157-3"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1532248"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.5604\/17331331.1185912"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy257"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1177\/1751143718794127"},{"issue":"3","key":"cit0032","first-page":"116","volume":"77","author":"Houweling BM","year":"2019","journal-title":"Neth J Med"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819002152"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1371\/currents.outbreaks.b50c2aaf1032b3ccade0fca0b63ee518"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30253-5"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1557520"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e3283574c06"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1451810"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1878030"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3180cc2c25"},{"key":"cit0041","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Mbaeyi S","year":"2015","edition":"13"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.3"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111675"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101521"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09946-1"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1990"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S159952"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0254-1"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1729030"},{"key":"cit0050","unstructured":"European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Solna, Sweden: European Centre for Disease Prevention and Control; 2019 [updated 2019 Jan 7;2021 Jan 9]. Available from: https:\/\/www.ecdc.europa.eu\/en\/meningococcal-disease\/factsheet"},{"key":"cit0051","unstructured":"European Center for Disease Prevention and Control. Meningococcal disease: recommended vaccinations Solna, Sweden: European Center for Disease Prevention and Control; 2021 [2021 Feb 12]. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=\u22121"},{"key":"cit0052","unstructured":"European Medicines Agency. Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine) - summary of product characteristics. Amsterdam, The Netherlands. 2014 [updated 2014 Dec 4;2021 Jan 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/menveo-epar-product-information_en.pdf"},{"key":"cit0053","unstructured":"European Medicines Agency. Nimenrix (Meningococcal groups A, C, W-135 and Y conjugate vaccine) - summary of product characteristics. Amsterdam, The Netherlands: European Medicines Agency; 2017 [updated 2017 Feb 16;2021 Jan 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nimenrix-epar-product-information_en.pdf"},{"key":"cit0054","unstructured":"European Commission approves MenQuadfi\u00ae. The latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older [Internet]. Lyon, France: Sanofi; 2020; 2020 Nov 23. Available from: https:\/\/www.sanofi.com\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Global\/Sanofi-COM\/Home\/media-room\/press-releases\/2020\/2020-11-23-10-00-00-2131477-en.pdf"},{"key":"cit0055","unstructured":"European Medicines Agency. MenQuadfi\u00ae (Meningococcal Group A, C, W and Y conjugate vaccine) - summary of product characteristics. Amsterdam, The Netherlands: European Medicines Agency; 2020 [updated 2020 Nov 23;2021 May 15]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/menquadfi-epar-product-information_en.pdf"},{"key":"cit0056","unstructured":"United States Food and Drug Administration (FDA). Meningococcal (Groups A, C, Y, W) conjugate vaccine - BLA approval Rockville, MD: United States Food and Drug Administration (FDA); 2020 [updated 2020 Apr 23;2021 Jan 8]. Available from: https:\/\/www.fda.gov\/media\/137331\/download"},{"key":"cit0057","unstructured":"Australian Government - Department of Health: Therapeutic Goods Administration. MenQuadfi: Australian prescription medicine decision summary. Woden ACT, Australia: Australian Government, Department of Health; 2020 [2021 Feb 10]. Available from: https:\/\/www.tga.gov.au\/apm-summary\/menquadfi"},{"key":"cit0058","unstructured":"Government of Canada: Health Canada. Notice of Compliance Information: menQuadfi Ottawa, Canada: Government of Canada; 2020 [updated 2020 Oct 29;2021 Feb 28]. Available from: https:\/\/health-products.canada.ca\/noc-ac\/info.do?lang=en&no=24522"},{"key":"cit0059","unstructured":"Government of Brazil. Di\u00e1rio Oficial da Uni\u00e3o - Publicado em: 01\/02\/2021; Edi\u00e7\u00e3o: 21; Se\u00e7\u00e3o: 1; P\u00e1gina: 111 - \u00d3rg\u00e3o: minist\u00e9rio da Sa\u00fade\/Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria\/2\u00aa Diretoria\/Ger\u00eancia-Geral de Medicamentos e Produtos Biol\u00f3gicos - Resolu\u00e7\u00e3o Re N\u00ba 384, De 28 de Janeiro De 2021 Brasilia, Brazil: Government of Brazil; 2021 [updated 2021 Jan 28;2021 Mar 16]. Available from: https:\/\/www.in.gov.br\/en\/web\/dou\/-\/resolucao-re-n-384-de-28-de-janeiro-de-2021-301574612"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733869"},{"key":"cit0061","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1017\/S0950268821000261","volume":"149","author":"van der Vliet D","year":"2021","journal-title":"Epidemiol Infect"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002832"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.017"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.013"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733867"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1733868"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.067"},{"issue":"90","key":"cit0068","first-page":"1","volume":"149","author":"Dhingra MS","year":"2021","journal-title":"Epidemiol Infect"},{"key":"cit0069","unstructured":"United States Centers for Disease Control and Prevention. Clinical Update: Menomune (meningococcal polysaccharide vaccine) discontinuation Atlanta, Georgia: Centers for Disease Control and Prevention; 2017 [updated 2017 Mar 24;2021 Feb 28]. Available from: https:\/\/wwwnc.cdc.gov\/travel\/news-announcements\/menomune-discontinuation"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318268dfe4"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0155-7"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1593082"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318212eb80"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.5.810"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199608000-00010"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(86)90048-0"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890320310"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(91)90266-9"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1902701"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05460-11"},{"issue":"1","key":"cit0083","first-page":"108","volume":"10","author":"Opalka D","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1452576"},{"key":"cit0085","unstructured":"Public Health England. Meningococcal ACWY conjugate vaccination (MenACWY). London, UK: Public Health England; 2015 [updated 2015 Jun 22; 2021 Apr 5]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/437901\/150622_ACWY_bipartite_letter.pdf"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-35"},{"issue":"1","key":"cit0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.anpedi.2019.10.007","volume":"92","author":"\u00c1lvarez Garc\u00eda FJ","year":"2020","journal-title":"An Pediatr (Barc)"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.013"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.045"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.064"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.034"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.10.003"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.10.015"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28206"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1051276"},{"key":"cit0096","volume-title":"38th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID)","author":"Findlow J","year":"2020"},{"key":"cit0097","first-page":"1","volume":"19","author":"Serra L","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6506a4"},{"issue":"1","key":"cit0099","first-page":"1","volume":"35","author":"Samad F","year":"2021","journal-title":"Pharmaceut Med"},{"key":"cit0100","unstructured":"Prevos BME, Boumans RJ Reduction of errors in vaccine preparation: a matter of technique or craftsmanship? Bilthoven, The Netherlands: National Institute for Public Health and the Environment, Minstry of Health, Welfare, and Sport; 2019 [2021 Feb 11]. Available from: https:\/\/magazines.rivm.nl\/2019\/04\/infectieziekten-bulletin\/vermindering-van-fouten-bij-vaccinbereiding-een-kwestie-van"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.045"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.030"},{"issue":"2","key":"cit0103","first-page":"E107","volume":"59","author":"Orsi A","year":"2018","journal-title":"J Prev Med Hyg"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1873770"},{"key":"cit0105","unstructured":"United States National Library of Medicine. A study of a quadrivalent meningococcal tetanus protein conjugate vaccine in infants and toddlers (MET39; NCT01049035). Bethesda, MD: National Institutes of Health; 2020 [updated 2020 Jun 9;2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01049035"},{"key":"cit0106","unstructured":"United States National Library of Medicine. Immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine when co-administered with routine pediatric vaccines in healthy infants and toddlers in Europe (MET58; NCT03547271). Bethesda, MD: National Institutes of Health; 2020 [2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03547271"},{"key":"cit0107","unstructured":"United States National Library of Medicine. Safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with routine pediatric vaccines in healthy infants and toddlers (MET41; NCT03673462) Bethesda, MD: National Institutes of Health; 2020 [updated 2020 Oct 28;2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03673462"},{"key":"cit0108","unstructured":"United States National Library of Medicine. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in the US (MET42; NCT03537508) Bethesda, MD: National Institutes of Health; 2021 [updated 2021 Feb 9;2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03537508"},{"key":"cit0109","unstructured":"United States National Library of Medicine. Immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine administered concomitantly with routine pediatric vaccines in healthy infants and toddlers (MET61; NCT03691610) Bethesda, MD: National Institutes of Health; 2021 [updated 2021 Jan 6;2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03691610"},{"key":"cit0110","unstructured":"United States National Library of Medicine. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in infants and toddlers when administered concomitantly with routine pediatric vaccines in the United Kingdom (MET52; NCT03632720) Bethesda, MD: National Institutes of Health; 2021 [updated 2021 Jan 6;2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03632720"},{"key":"cit0111","unstructured":"United States National Library of Medicine. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in the Russian federation and Mexico (MET33; NCT03630705) Bethesda, MD: National Institutes of Health; 2021 [updated 2021 Jan 6;2021 Feb 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03630705"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040624"},{"key":"cit0113","volume-title":"31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); July 9-12, 2021; Virtual Conference","author":"Knuf M","year":"2021"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1746110"},{"key":"cit0115","unstructured":"United States National Library of Medicine. Study to evaluate the immune response after a booster dose of a quadrivalent meningococcal (MenACYW) conjugate vaccine when administered alone or concomitantly with a licensed meningococcal serogroup B vaccine,in participants who received primary quadrivalent meningococcal conjugate vaccine (MCV4) (MET59; NCT04084769) Bethesda, MD: National Institutes of Health; 2021 [updated 2021 Feb 1;2021 Apr 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04084769"},{"key":"cit0116","unstructured":"World Health Organization (WHO). WHO expert committee on biological standardization: twenty-seventh report 1976 [2021 Feb 11]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37954\/WHO_TRS_594.pdf?sequence=1%26isAllowed=y"},{"issue":"7","key":"cit0117","first-page":"1","volume":"54","author":"Bilukha OO","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"cit0118","first-page":"273","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"cit0119","first-page":"888","volume-title":"Abstract presented at: 37th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); May 6-11, 2019; Ljubljana, Slovenia","author":"Vesikari T","year":"2019"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.4155\/cli.12.52"},{"key":"cit0121","unstructured":"World Health Organization (WHO). Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A\/C vaccines Geneva, Switzerland: World health Organization; 1999 [2021 Feb 12]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/66298\/WHO_V&B_99.19.pdf?sequence=1"},{"issue":"47","key":"cit0122","first-page":"521","volume":"86","author":"World Health Organization (WHO)","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8732191"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000868"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31820a8b3c"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2193"},{"key":"cit0127","unstructured":"United States Food and Drug Administration. Menomune\u00ae \u2013 A\/C\/Y\/W-135 vaccine Rockville, MD: United States Food and Drug Administration; 2016 [updated 2016 Apr 1;2021 Feb 28]. Available from: https:\/\/www.fda.gov\/media\/83562\/download"},{"key":"cit0128","unstructured":"United States Food and Drug Administration. Menactra\u00ae - prescribing information Rockville, MD: United States Food and Drug Administration; 2019 [2021 Feb 28]. Available from: https:\/\/www.vaccineshoppe.com\/image.cfm?doc_id=12580&image_type=product_pdf"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2021.1964962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T07:23:55Z","timestamp":1650525835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2021.1964962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":128,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/14760584.2021.1964962"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2021.1964962","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}